Articles Tagged With:
-
Is Planned Complete Revascularization After Myocardial Infarction Wise for Older Patients?
Among patients at least age 75 years presenting with acute myocardial infarction and multivessel coronary disease, physiology-guided complete revascularization led to a lower risk of major adverse cardiovascular events at one year vs. culprit lesion-only percutaneous coronary intervention.
-
High-Impact Clinical Trials from the European Society of Cardiology Congress 2023
The following is an overview of important cardiology research presented Aug. 25 through Aug. 28 in Amsterdam and online during the ESC Congress 2023.
-
The Hemodynamic Effects of an SGLT2 Inhibitor in Heart Failure with Preserved Ejection Fraction
The authors of a small, placebo-controlled study of 24 weeks of dapagliflozin therapy in patients with heart failure with preserved ejection fraction reported reductions in pulmonary capillary wedge pressure, which may explain the reductions in heart failure hospitalizations or cardiovascular death in larger randomized outcome trials.
-
Is the Combination of a GLP-1 Agonist and a SGLT2 Inhibitor Safe?
Adding a GLP-1 RA in a subgroup of type 2 diabetes patients on baseline SGLT2 inhibitor therapy revealed GLP-1 RA reduces major adverse cardiovascular event rates, regardless of baseline SGLT2 use.
-
An RNA Shot for Hypertension?
One dose of a new RNA-based drug administered by subcutaneous injection, which blocks hepatic angiotensinogen production, resulted in sustained reductions in blood pressure in patients with hypertension for up to 24 weeks without any serious adverse effects.
-
Does Current IRB System Ensure Ethical Research?
A consensus is needed for how to measure IRB quality or effectiveness, and more inspections are needed to ensure instances of IRB noncompliance are identified, according to the authors of a recent report.
-
Growing Concerns About Health Data Use
A group recently outlined ethical, legal, and societal standards for data collection, use, and reuse to which researchers, technology companies, and others can be held accountable. The statement assures people the stewardship of their data is taken seriously, and that the company is committed to using it ethically.
-
Patients Say Researchers Are Ethically Obligated to Return Study Data
Returning patient-reported outcome data to study participants is a growing priority for researchers. it is important to do it in a way that is comprehensible, actionable, and aligned with participants’ preferences.
-
To Pay or Not to Pay: Researchers Grapple with Implications of Reimbursing Study Participants
Pushback on paying participants comes from both researchers and IRBs. From the researcher’s perspective, concerns revolve around budgetary limitations and how much they can afford to pay. IRBs generally are more concerned about payment amounts causing undue influence on participation.
-
Literature Review Reveals Gaps in Research on Assisted Reproductive Technologies
Ethicists should consider the potential for discrimination and inequality in access to assisted reproductive technologies, and help make these solutions available to all who need them, regardless of their socioeconomic status, race, ethnicity, or other factors.